Compare ASTC & MDCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ASTC | MDCX |
|---|---|---|
| Founded | 1984 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.5M | 10.9M |
| IPO Year | 2020 | 2025 |
| Metric | ASTC | MDCX |
|---|---|---|
| Price | $4.82 | $1.85 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $203.75 |
| AVG Volume (30 Days) | 25.8K | ★ 65.7K |
| Earning Date | 11-12-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 2600.00 | N/A |
| EPS | ★ 0.25 | N/A |
| Revenue | ★ $1,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $21.40 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.92 | $2.12 |
| 52 Week High | $68.85 | $127.50 |
| Indicator | ASTC | MDCX |
|---|---|---|
| Relative Strength Index (RSI) | 32.20 | 16.78 |
| Support Level | $4.63 | N/A |
| Resistance Level | $7.76 | $8.55 |
| Average True Range (ATR) | 0.41 | 0.35 |
| MACD | 0.02 | 0.09 |
| Stochastic Oscillator | 19.55 | 3.23 |
Astrotech Corp is a science and technology company. It creates, operates and scales businesses through its subsidiaries and technology platforms, including space-related technology, instrumentation, mass spectrometry, gas chromatography, process-control and environmental analysis technologies. It is evaluating opportunities to identify, develop and commercialize technologies with potential applications in space, defense, industrial, environmental, quantum computing, AI, semiconductor materials, lunar infrastructure and related markets. Its products include Tracer 1000 ETD, tracer 1000 NTD, Labrador HHGC, Fenceline GC, AgLab 1000-D2, among others. It operates in single segment.
Medicus Pharma Ltd is a clinical-stage, life sciences, biotech company focused on investing in and accelerating clinical development programs of novel and potentially disruptive therapeutic assets. The company has one operating segment.